卡里斯生命科学公司提交了首次公开募股的注册声明-动脉网

Caris Life Sciences Files Registration Statement for Proposed Initial Public Offering

CISION 等信源发布 2025-05-24 05:54



可切换为仅中文







IRVING, Texas

德克萨斯州欧文市

，

May 23, 2025

2025年5月23日

/PRNewswire/ -- Caris Life Sciences

('Caris'), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission ('SEC') relating to a proposed initial public offering of its Class A common stock.

卡里斯（Caris），一家领先的、以患者为中心的下一代人工智能技术生物公司和精准医疗先锋，今天宣布已就其A类普通股拟议首次公开募股向美国证券交易委员会（SEC）提交了S-1表格的注册声明。

The number of shares to be offered and the price range for the proposed offering have not yet been determined. Caris has applied to list its Class A common stock on the Nasdaq Global Select Market under the ticker symbol 'CAI.'.

发行的股份数量和建议发行的价格范围尚未确定。Caris已申请将其A类普通股在纳斯达克全球精选市场上市，股票代码为“CAI”。

BofA Securities, J.P. Morgan and Goldman Sachs & Co. LLC will act as lead book-running managers for the proposed offering. Citigroup will also act as a book-running manager for the proposed offering. TD Cowen, Evercore ISI and Guggenheim Securities will act as additional book-running managers for the proposed offering.

美银证券、摩根大通和高盛有限责任公司将担任此次拟议发行的首席簿记管理人。花旗集团也将担任此次拟议发行的簿记管理人。TD Cowen、Evercore ISI 和 Guggenheim Securities 将担任此次拟议发行的额外簿记管理人。

BTIG and Wolfe | .

BTIG 和 Wolfe | 。

Nomura Alliance

野村联盟

will act as co-managers for the proposed offering.

将作为拟议发行的共同经理人。

The proposed offering will be made available only by means of a prospectus. Copies of the preliminary prospectus, when available, may be obtained from: BofA Securities, NC1-022-02-25, 201 North Tryon Street,

拟议的发行仅通过招股说明书进行。初步招股说明书的副本（一旦可用）可从以下地址获取：BofA Securities，NC1-022-02-25，201 North Tryon Street，

Charlotte, North Carolina

北卡罗来纳州夏洛特市

28255, Attention: Prospectus Department or by email:

28255，注意：招股说明书部门或电子邮件：

dg.prospectus_requests@bofa.com

; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,

；摩根大通证券有限责任公司，转交布罗德里奇金融解决方案，长岛大道1155号，

Edgewood, New York

纽约州埃奇伍德

11717 or by email:

11717 或通过电子邮件：

prospectus-eq_fi@jpmchase.com

招股说明书-eq_fi@jpmchase.com

; or Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street,

; 或高盛集团有限公司，致：招股说明书部门，西街200号，

New York, New York

纽约，纽约

10282 or by email:

10282 或通过电子邮件：

prospectus-ny@ny.email.gs.com

招股说明书-纽约@纽约.电子邮件.高盛.com

。

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction..

与这些证券相关的注册声明已提交给美国证券交易委员会（SEC），但尚未生效。在注册声明生效之前，不得出售这些证券，也不得接受购买要约。本新闻稿不构成出售这些证券或征求购买这些证券的要约，在任何该类州或司法管辖区的证券法规定注册或资格之前，此类要约、征求或出售属违法的任何州或司法管辖区，也不得进行任何这些证券的销售。

About Caris Life Sciences

关于Caris生命科学

Caris Life Sciences

卡里斯生命科学

(Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease.

Caris是一家领先的、以患者为中心的下一代AI技术生物公司，也是精准医学的先驱，正在积极开发和商业化创新解决方案以变革医疗保健。通过全面的分子分析（全外显子组和全转录组测序）以及大规模应用先进的AI和机器学习算法，Caris创建了大规模、多模态的临床基因组数据库和计算能力，用以分析并进一步揭示疾病的分子复杂性。

This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development..

下一代测序、人工智能和机器学习技术以及高性能计算的结合，为开发最新一代先进的精准医疗诊断解决方案提供了独特的平台，可用于早期检测、诊断、监测、治疗选择和药物开发。

Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in

卡里斯成立于一个信念和愿景，即结合大量持续生成的分子信息与强大的数据驱动洞察力，可以实现精准医疗对患者的潜力。总部位于

Irving, Texas

欧文，德克萨斯州

, Caris has offices in

，卡里斯在以下地点设有办事处

Phoenix, New York

纽约州凤凰城

，

Cambridge

剑桥

(MA),

（MA），